BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Synthekine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Synthekine's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05098132-2743@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:STK-012: Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:STK-012\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of STK-012 Alone and With Other Treatments in Patients With Advanced Lung
  Cancer and Other Cancers\nEstimated primary completion: January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/stk-012#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05098132
URL:https://assetmemo.bio/drug/stk-012#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
